Wicker said he is working with the Trump administration on a review of mifepristone policy
Work with the Trump administration on a review of mifepristone policy.
Occurrences
Evidence
unverified · Source version 1450 · locator unknown
FDA Commissioner of Food and Drugs Martin Makary committed to conduct a review of mifepristone.
unverified · Source version 1449 · locator unknown
At the same time, I am working with the Trump administration as it conducts a review of mifepristone policy.
unverified · Source version 1449 · locator unknown
Wicker says he is working with the Trump administration while it conducts a review of mifepristone policy.
unverified · Source version 1450 · locator unknown
The White House page says FDA Commissioner Martin Makary committed to conduct a mifepristone review.
unverified · Source version 62530 · locator unknown
Wicker stated: "I am working with the Trump administration as it conducts a review of mifepristone policy."
unverified · Source version 1450 · locator unknown
The White House listed as an administration action: "FDA Commissioner of Food and Drugs Martin Makary committed to conduct a review of mifepristone."
unverified · Source version 62530 · locator unknown
At the same time, I am working with the Trump administration as it conducts a review of mifepristone policy.
unverified · Source version 74491 · locator unknown
The Food and Drug Administration is conducting a review of the abortion drug mifepristone.
unverified · Source version 74493 · locator unknown
It is ORDERED that this action is STAYED until the sooner of December 1, 2026 or FDA’s completion its review of the Challenged Actions.
unverified · Source version 86968 · locator unknown
FDA is conducting a study to assess the safety of mifepristone, in a regimen with misoprostol, for the medical termination of intrauterine pregnancy though 70 days gestation.
unverified · Source version 86968 · locator unknown
FDA is on track to obtain study results by mid-December 2026. FDA will then need to review and evaluate/interpret the results and draft a report. FDA expects to complete that process not later than March 2027.
Assessments
Wicker's June 1, 2026 Senate statement directly says he was working with the Trump administration as it conducted a mifepristone policy review. The White House also corroborated that FDA Commissioner Martin Makary had committed to such a review. Because the promise was to work with the administration on the review, not to secure a final policy change, the available candidate-specific evidence supports full delivery during his current Senate term.
The promise was to work with the Trump administration on a review of mifepristone policy, and Wicker explicitly stated on June 1, 2026 that he was doing exactly that while the administration conducted the review. Separate White House evidence from June 4, 2026 confirms the administration-side review was in fact underway, which supports that his claimed collaboration corresponded to a real federal process. Because the commitment was about participating in the review rather than securing a final policy change, this constitutes delivery in the same term.
Wicker’s own June 1, 2026 statement says he was working with the Trump administration as it conducted a review of mifepristone policy, which directly matches the claim. The White House evidence also confirms the administration-side review was underway in the same period. This is a candidate-specific, in-office action, so it counts as delivered in the same term.